These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35585949)

  • 1. Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report.
    Wada TT; Yokota K; Iida S; Kanno Y; Shinozuka N; Sato K; Asanuma YF; Yamamoto K; Mimura T
    J Scleroderma Relat Disord; 2022 Jun; 7(2):NP4-NP8. PubMed ID: 35585949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
    Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
    J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report.
    Chida-Nagai A; Tsujioka T; Sasaki D; Izumi G; Yamazawa H; Takeda A
    Front Pediatr; 2022; 10():909595. PubMed ID: 35783314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Rescue treatment with add-on selexipag in a preterm infant with suprasystemic pulmonary hypertension, pulmonary capillary hemangiomatosis, and isolated pulmonary vein stenosis.
    Hasan H; Hysko K; Jack T; Dingemann J; Wetzke M; Hansmann G
    Front Cardiovasc Med; 2022; 9():984698. PubMed ID: 36568561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
    Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series.
    Lemmers JM; Fretheim H; Knaapen HK; van den Hoogen FH; van Haren-Willems JH; Duijnhouwer AL; van Dijk AP; van den Ende CH; Hoffmann-Vold AM; Vonk MC
    J Scleroderma Relat Disord; 2020 Oct; 5(3):NP7-NP11. PubMed ID: 35382522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.
    Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
    J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators.
    Kusaka K; Nakano K; Fukuyo S; Miyazaki Y; Matsunaga S; Tanaka Y
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):203-208. PubMed ID: 35274731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary hypertension associated with veno-occlusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator.
    Tada H; Konno T; Aizu M; Yokawa J; Tsubokawa T; Fujii H; Hayashi K; Uchiyama K; Matsumura M; Kawano M; Kawashiri MA; Yamagishi M
    J Cardiol Cases; 2012 Feb; 5(1):e44-e47. PubMed ID: 30532900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Thurber KM; Williams BM; Bates RE; Frantz RP
    Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.